ENTITY
Samsung Biologics

Samsung Biologics (207940 KS)

303
Analysis
Health CareSouth Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
Refresh
30 Nov 2021 12:08

Asymchem Labs A/​H Listing - Pricing Seems Adequate Despite the Share Price Run Up

Asymchem Laboratories (AL) aims to raise up to US$968m in its H-share listing in Hong Kong. In this note, we will talk about the IPO pricing.

Logo
240 Views
Share
21 Nov 2021 08:29

Asymchem Labs A/H Listing - PHIP Updates and a Look at Valuations

Asymchem Laboratories (AL) aims to raise around US$1-1.5bn in its H-share listing in Hong Kong. In this note, we talk about recent updates, peer...

Logo
270 Views
Share
bullishSK Inc
04 Oct 2021 20:09

SK Inc - SoTP Valuation Analysis and 3 Key Catalysts (SK E&S, SK Pharmteco, & SK Siltron)

In this insight, we provide an updated NAV valuation analysis of SK Inc. Our updated base case valuation of SK Inc is 381,838 won per share,...

Logo
300 Views
Share
04 Sep 2021 06:03

Asia Shorts: Alibaba, CMB, Tencent, Anta, Shiseido, Odakyu, Keio, NC Soft, LGD, SK Tel, Evergreen

The Insight looks at movements in short interest across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
217 Views
Share
25 Aug 2021 08:42

AmbioPharm (昂博制药) Pre-IPO: Peptide CDMO Leader Turning Licensor

AmbioPharm is a global leader in the peptide CDMO business and will further monetizing its expertise by collaborating with partners to develop...

Logo
797 Views
Share
x